Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study

Table 4 Regional hemodynamics

	Baseline	12 hours	24 hours	36 hours	48 hours
CBI (mL/min/m)
TP	353 ± 226	387 ± 202	367 ± 179	299 ± 139	351 ± 129
AVP	397 ± 171	409 ± 209	367 ± 222	308 ± 185*	305 ± 201*
NE	327 ± 135	358 ± 173	312 ± 145	271 ± 136	252 ± 206
PDR (%)
TP	13 ± 6	14 ± 5	13 ± 4	12 ± 5	13 ± 4
AVP	15 ± 5	15 ± 6	13 ± 7	12 ± 7*	11 ± 6*
NE	14 ± 5	13 ± 5	12 ± 6	11 ± 6*	10 ± 7*
P _g-a CO ₂ (mmHg)
TP	23 ± 11	24 ± 8	22 ± 6	20 ± 6	20 ± 7
AVP	25 ± 7	28 ± 8	27 ± 9	28 ± 12	28 ± 10
NE	24 ± 11	28 ± 10	28 ± 8	26 ± 8	31 ± 12
Urinary output (mL/h)
TP	34.6 ± 31.3	69.3 ± 70.4	49.2 ± 49.5	48.5 ± 41.4	46.6 ± 33.3
AVP	42.3 ± 46.9	42 ± 39	42 ± 41.6	40.7 ± 45.7	43.3 ± 58.7
NE	38.6 ± 34.3	55.4 ± 74.1	66 ± 77	58.6 ± 56.1	58.6 ± 63.8

AVP = arginine vasopressin; CBI = blood clearance of indocyanine green; NE = norepinephrine; PDR = plasma disappearance rate of indocyanine green; P_g-aCO₂ = gastric-mucosal arterial carbon dioxide partial pressure difference; TP = terlipressin.
* P < 0.05 vs. baseline (significant time effect); ^† P < 0.05 vs. TP (significant group effect); ^‡ P < 0.05 vs. AVP (significant group effect); ^§ P < 0.05 vs. NE (significant group effect).

ISSN: 1364-8535